Data from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study

Abstract

<div>Abstract<p><b>Purpose:</b> Histologic markers that differentiate benign and malignant pediatric adrenocortical tumors are lacking. Previous studies have implicated an association of MHC class II expression with adrenocortical tumor prognosis. Here, we determined the expression of MHC class II as well as the cell of origin of these immunologic markers in pediatric adrenocortical tumor. The impact of MHC class II gene expression on outcome was determined in a cohort of uniformly treated children with adrenocortical carcinomas.</p><p><b>Experimental Design:</b> We analyzed the expression of MHC class II and a selected cluster of differentiation genes in 63 pediatric adrenocortical tumors by Affymetrix Human U133 Plus 2.0 or HT HG-U133+PM gene chip analyses. Cells expressing MHC class II were identified by morphologic and immunohistochemical assays.</p><p><b>Results:</b> MHC class II expression was significantly greater in adrenocortical adenomas than in carcinomas (<i>P</i> = 4.8 ×10<sup>−6</sup>) and was associated with a higher progression-free survival (PFS) estimate (<i>P</i> = 0.003). Specifically, <i>HLA-DPA1</i> expression was most significantly associated with PFS after adjustment for tumor weight and stage. <i>HLA-DPA1</i> was predominantly expressed by hematopoietic infiltrating cells and undetectable in tumor cells in 23 of 26 cases (88%).</p><p><b>Conclusions:</b> MHC class II expression, which is produced by tumor-infiltrating immune cells, is an indicator of disease aggressiveness in pediatric adrenocortical tumor. Our results suggest that immune responses modulate adrenocortical tumorigenesis and may allow the refinement of risk stratification and treatment for this disease. <i>Clin Cancer Res; 22(24); 6247–55. ©2016 AACR</i>.</p></div>